Oh, did you hear....?
quote.bloomberg.com
PROMINENT MEDICAL JOURNAL TO PUBLISH STUDY ON REVOLUTIONARY COLD
Remedy;
Zicam Reduced Duration of Common Cold by an Average of 85%
WOODLAND HILLS, Calif., Nov. 1 /PRNewswire/ -- The professional
peer-reviewed American Journal of Infection Control (AJIC) will publish the
results of a scientific study on Zicam(TM), a revolutionary over-the-counter
homeopathic cold remedy. According to the initial study, a proprietary nasal
solution, currently marketed as Zicam(TM), reduced the duration of the common
cold by an average of 85% and significantly reduced the severity of colds
including nasal congestion, sneezing, coughing, and sore throat.
AJIC, first published in 1973, is the official scientific publication of
the American Association of Professionals in Infection Control and
Epidemiology (APIC). In addition to peer-reviewed articles and original
research across the field of infection control and epidemiology, including
occupational health and disease prevention, AJIC publishes the official
guidelines for infection control practices produced by APIC and the CDC (the
Centers for Disease Control and Prevention).
"This initial research on Zicam is quite significant. The term 'cure' is
not scientifically applicable since the common cold is a self-limiting
condition, but the degree of efficacy of the medication demonstrated by this
first study is very impressive," said Dr. Michael Seidman, MD, FACS, a medical
consultant to the company in the Department of Otolaryngology at Henry Ford
Medical Center, Detroit, Michigan.
The Study
"This initial clinical research showed that participants who used
Zicam(TM) at the onset of symptoms significantly reduced the duration of their
colds," said Dr. Charles B. Hensley, chief of research at Gel Tech, LLC. The
double blind placebo-controlled study was conducted by scientists from Gel
Tech over a two-cold season period. A total of 104 subjects presenting with
at least 3 of 9 cold symptoms for a period of 24 hours or less participated in
the study. Patients received a dosage of either the proprietary nasal gel
containing the active ingredient or a placebo 4 times daily. Colds were
determined to be over when all symptoms were resolved. Subjects receiving the
active ingredient found in Zicam(TM) had colds which lasted only 1.5 days on
average, while subjects receiving the placebo had colds which lasted 9.8 days
on average.
The Common Cold
The common cold is generally caused by an estimated two hundred viruses
known as rhinoviruses (rhino means nose). These viruses, which primarily
infect the upper respiratory tract, may enter the body through the nose, mouth
or eyes, with the infection cycle beginning in the nasal cavity. Inside the
nasal cavity, the virus infects the body by binding to ICAM-1 (Intercellular
adhesion molecule-1) receptor sites located on the cells that line the nasal
passageway. The virus enters those cells through the ICAM-1 binding site, and
then uses the cells' own genetic material to replicate and infect the body.
As the virus infects more and more nasal cells, the body's immune system is
overwhelmed, leading to a full-blown cold.
Aside from the personal misery caused by the common cold during the
average 10 - 14 day infection cycle, colds have a significant economic impact
on society. Of the estimated one billion common colds that occur each year in
the United States alone, more than 110 million are disabling, causing
approximately 300 million days of restricted activity, 60 million lost days of
school, and 50 million lost days of work. $5.5 billion is spent on colds (not
including prescription medicines) each year in the United States with about
$2.3 billion spent on over-the-counter cold remedies.
Zicam(TM)
"Unlike most other OTC and prescription cold remedies, which typically
were designed only to suppress or mask cold symptoms, Zicam(TM) was designed
to treat the duration and severity of the cold," said Dr. Hensley. Research
suggests that ionic zinc fills the grooves or canyons on the rhinovirus thus
inhibiting or blocking the virus's ability to bind with the ICAM-1 receptor
sites on the cells lining the nasal cavity, preventing or interrupting the
infection cycle. Zicam uses a patent-pending gel matrix to apply a
proprietary emulsification of ionic zinc, known as Zinullose(TM), directly to
the nasal cavity.
Zicam(TM) is developed by Gel Tech, LLC, a joint venture between GumTech
International, Inc., (Nasdaq: GUMM) a publicly held company located in
Phoenix, AZ and BioDelivery Technologies, Inc., a privately held biotechnology
company. Gum Tech and BDT are devoted to the development of unique systems
for delivering bioactive compounds.
Zicam(TM) is currently available at Drug Stores, Grocery Stores,
Pharmacies, Mass Merchants, Club Stores and Convenience Stores nationwide.
For more information, call 1-877-942-2626 or log onto www.zicam.com.
Life is liable to get pretty exciting for you, soon. |
